"No Blood, No Fasting, No Waiting" Article Written by Bob Moriarty of 321Gold.com

Excerpt from the Article:

"Their primary product is revolutionary. They own the rights to a machine that uses a frequency of light to fluoresce biomarkers in the skin to predict pre-diabetes and Type 2 diabetes. It’s totally non-invasive, no blood, no fasting, no waiting."

Full Article: http://www.321gold.com/editorials/moriarty/moriarty012615.html

"No Blood, No Fasting, No Waiting" Article Written by Bob Moriarty of 321Gold.com

Excerpt from the Article:

"Their primary product is revolutionary. They own the rights to a machine that uses a frequency of light to fluoresce biomarkers in the skin to predict pre-diabetes and Type 2 diabetes. It’s totally non-invasive, no blood, no fasting, no waiting."

Full Article: http://www.321gold.com/editorials/moriarty/moriarty012615.html

Great article on $PAF via the Financial Post.

Pan American Fertilizer Plans Its Medical Marijuana Strategy

It’s a one-two punch at Pan America Fertilizer, a small TSX-Venture listed company whose business is in “providing fertilizer to growing global markets specifically in South and Central America.”

On Friday, the company that has a market cap of $6-million announced an expansion of its operation to Uruguay while maintaining its base in Argentina. Establishing operations in Uruguay will, it said, ensure that it’s “on track to grow its market share, as fertilizer providers, within the agricultural industry of South America.” Uruguay was chosen to allow the company to capitalize on that country’s agricultural market as well as allow for “diversity’ in the types of products on which its fertilizer can be used.”

On Tuesday Pan American announced the second shoe: an intention to raise $500,000 by way of a non-brokered private placement. It’s understood Pan American limited the amount it wants to raise because of its desire to maintain a tight capital structure. In time the hope would be to raise additional capital – but at higher prices.

The cash raised from its current offering, will be used, in part, to expand into Uruguay, a county that has also received an investment from Dundee Agricultural Corp., a unit of Dundee Corp.

DAC has made a strategic investment in privately held Union Group International Holdings that was founded by Juan Sartori, a Uruguayan entrepreneur, who has expanded into real estate and mining from his original agriculture base.

So what are the plans?

In short, Pan American plans to get into the medical marijuana business. Indeed Uruguay will be the testing ground for the company’s existing products as well as developing new blends for medical marijuana and other crops. But Pan America has no plans to get into the production and distribution of medical marijuana – a business that becomes legal next month — in Uruguay. (In April, producing medical marijuana under a government licence also gets underway in Canada. At least one of those companies, Tweed Inc., will be public.)

According to a source familiar with Pan American’s plans, the company is not looking to grow marijuana to sell to the market. Rather it is planning a long-term study of its products with a view to increasing the yield of marijuana and other important high value crops.

Pan American will move into that industry by working with scientists on the development of an outdoor marijuana grow-op testing centre that will use its fertilizer and/or additives. The aim is to use its products to produce higher quality medical marijuana or other crops.

Accordingly, Pan American argues that the best way to make a return for its investors in the medical marijuana market, is not through growing the stuff – but to help those who have that goal by supplying them the best and most productive set of raw materials.

And Pan American may seek joint venture partners to help finance the purchase of operating assets – and avoid dilution of its existing shareholders. If the government of Uruguay allows widespread commercial production of marijuana, in the next few years, then Pan American may be in a good position to develop its base.

Certainly the market has taken notice of the company. According to Bloomberg, recent trading has jumped to many times the daily normal while the share price has also risen. It closed Tuesday at $0.175 – or about four times the level of one month back.


SOURCE: http://business.financialpost.com/2014/03/18/pan-american-plans-its-medical-marijuana-strategy/

"Time To Revalue IntelGenx - 2 More Products Being Reviewed By The FDA For Approval"

A Seeking Alpha article written by contributor 'ccamire'

Source: http://seekingalpha.com/instablog/192072-ccamire/2067722-time-to-revalue-intelgenx-2-more-products-being-reviewed-by-the-fda-for-approval

IGXT is a drug delivery company developing improved formulations of approved drugs for North America. IGXT has already succeeded to get one FDA approved drug using its proprietary technology: Late in 2012, Forfivo XL™ (the only single tablet high dose alternative to lower dose multiple tablet Wellbutrin XL® indicated for depression), was launched by Edgemont Pharma in the US. However the success of this small-cap based in Montreal (Canada) stands much deeper given its strong pipeline of products. Let's focus for now on just two new drugs that are now late stage and could be launched within the next 12-18 months.

IntelGenx has unique skills in developing improved drugs and has been very successful given the amount of capital invested. Investors should not forget that the company has raised less than $15m since its inception in 2003, has one drug approved and two drugs in the waiting room. Investors should also know the odds favors IntelGenx to receive approval for both drugs given reformulated drugs have an overall approval rate >90% compared to new chemical entities or NCEs below 30%.

First, the announcement this week for a US filing for a generic of Suboxone film (buprenorphine and naloxone for the treatment of opioid addiction.) for a relatively large market should be a wake-up call for investors. The product is likely to be first generic to market in the fast growing market $1.4bn (tablets and film version almost divided equally). It is difficult to predict what Reckitt Benckiser Pharmaceuticals, the brand manufacturer, will do given its sizeable contribution to profits for the company. Currently patients must be medicated 3x/day; therefore an annual treatment between $4,300- $7,700 depending on the dose. In recent years, the market has shifted from tablets to film formulation to reduce side effects and be cheaper, which is good news for IGXT. Therefore the potential for this product could be huge given that film revenues have increased by 50% versus the prior year. Usually first generic companies capture 60-70% of revenues for the exclusive period (normally six months). Contrary to tablet formulation, where there are many generic companies (>300), makers of film products are very few, probably less than ten in the world. High barriers to entry in formulating this product provide a huge potential upside for IGXT. Therefore we would expect IGXT could enjoy a leadership position beyond six months. Assuming a conservative $1.5bn market at the time of market launch, a 25% price discount and capturing a 50% market, this would means revenues in excess of $500m for its commercial partner. With IGXT being the manufacturer and collecting royalties, this drug itself could add a minimum of $2.00/share in EBITDA. However given the patents on this drug are still valid until 2022, I am not sure when IGXT could launch this drug, but I am sure management has spent time to figure a strategy to reach the marketplace as soon as feasible.

The other important piece of news (June 18) involved the filing for regulatory approval of a novel anti-migraine drug developed by IGXT. I find this product could be an extremely appealing drug in this market because it offers something really different versus the competition. Even though the US migraine market is close to $2.5bn (all tablet formulations), many patients do not respond to many drugs, are often required to try different treatments and for many are left without any adequate treatments. The advantage of IntelGenx' Anti-Migraine VersaFilm is that it acts faster than probably most drugs and it is also easier to swallow. Commercially this would be the first oral film product for IntelGenx. There are very few oral film drugs on the market; therefore its success will be closely monitored. Assuming a $600m market at the time of market launch, a 25% price discount and capturing a 25% market, this would means revenues in excess of $100m for its commercial partner. With IGXT being the manufacturer and collecting royalties, this drug itself could add $0.40-0.45/share in EBITDA in 2015.

These drugs are not $1bn potential but they can certainly generate significant revenues with a smaller investment and much lower risks than a typical cancer drug.

Over the next 2 years, we should expect more drugs that could be launched or in the queue for regulatory approval with the FDA. I believe very few companies have accomplished this feat. We see too many catalysts to ignore the story. Given the company has already delivered on many fronts, drug delivery companies such as IGXT should not be ignored. This is much easier to swallow.

Scientific Study Reveals ReadiDiesel® Meets Petroleum-Based Diesel Specifications Without Blending Fossil Fuels

Source: http://bit.ly/19kX881

June 24, 2013 – Vancouver, British Columbia – Calyx Bio-Ventures Inc. (TSX-V: CYX) is
pleased to announce that Resonance® energy feedstock provided by Calyx subsidiary Agrisoma Biosciences, was found to be the most similar to petroleum-derived fuels as compared to other renewable fuels tested in a recent study conducted by the Coordinating Research Council (CRC), a non-profit organization that encourages, promotes and studies various fuels through scientific research.

The study, Advanced Alternative and Renewable Diesel Fuels: Detailed Characterization of
Physical and Chemical Properties, confirmed that ReadiDiesel®, made from Agrisoma’s
Resonance™ energy cairnata feedstock, “looked more like the petroleum-derived fuels than the
other renewable fuels…” The study compared the results of detailed analyses of the physical and chemical properties of 10 advanced alternative and renewable diesel fuels and four commercial ultra low sulfur diesels.

A key objective of the blind study was to identify the similarities and differences of alternative
and renewable fuels as compared to conventional petroleum derived diesel fuels. Samples were
obtained from select manufacturers who produced diesel on a relatively large scale (from pilot to
commercial scale) and agreed to participate in the study.

Highlights of the report include:
• Referring to RD3 (ReadiDiesel): “…looked more like the petroleum-derived fuels than
the other renewable fuels…” Page xviii, Executive Summary.

• ReadiDiesel was the only fuel tested that had the same level of aromatics as petroleumbased diesel fuel, the main reason most alternative fuels require blending with petroleum.

ReadiDiesel, made by Applied Research Associates (ARA) and Chevron Lummus Global from
Agrisoma Resonance® energy feedstock, is referred to as "RD3" in the report the report.
“The CRC report provides a broad view and comprehensive analysis of the slate of alternative
and renewable diesel fuels at or near commercial scale. Our ReadiDiesel, made from Agrisoma’s Resonance energy feedstock, clearly stands out, meeting D975 specs without blending and having a molecular makeup that is almost indistinguishable from the ultra low sulfur diesels tested in the program,” said Ed Coppola, ARA Fuels Technical Lead.

“The fact that ReadiDiesel has a density equivalent to petroleum diesels is significant from an
operational perspective as it equates to extra miles per gallon for a diesel fleet,” said Chuck Red,
ARA’s Vice President, Fuels Development.

“The CRC study is one more confirmation that Resonance® carinata can be used as a feedstock
for fuels that are complete petroleum substitutes, resulting in substantially reduced carbon and
other harmful emissions without compromising performance,” said Hugh Notman, president and
CEO of Calyx. “This further supports our efforts to become a leading non-food source of
biofuels that can be utilized seamlessly in petroleum-fuel powered engines, whether they be in
planes, ground transportation or other applications.”

Access to the full CRC Report visit http://www.crcao.org/reports/recentstudies2013/AVFL-19-
2/CRC%20Project%20AVFL-19-2%20Final%20Report.pdf

The AVFL-19 Working Group (of the CRC) is comprised of representatives from energy
companies, U.S. national labs, and a Canadian national lab. The time and testing expenses of the authors were largely funded by their respective organizations. Members of the U.S. Department of Energy National Laboratories used funding from their budgets provided by U.S. DOE Vehicle Technologies Program. Members of National Resources Canada and Canmet ENERGY used funding from their budgets provided by the Government of Canada’s interdepartmental Program of Energy Research and Development, PERD 113 Petroleum Conversion for Cleaner Air.

Golden Fame Resources and Pan American Fertilizer Sign Definitive Agreement

Vancouver, British Columbia, May 21, 2013: Golden Fame Resources Corp. (TSXV:GFA; Frankfurt: 6GF) ("Golden Fame") and Pan American Fertilizer Corp. (CNSX:PAF) ("Pan American") are pleased to announce that they have signed the definitive agreement (the "Arrangement Agreement") regarding the proposed business combination announced in their joint news release dated April 24, 2013.

For more: http://bit.ly/13IB1A0

IntelGenx: Looking Towards A Pivotal Year Ahead
Investment Highlights:
¦
Forfivo™ Traction Expected To Accelerate. We note that Forfivo™ has
now been available in the U.S. for roughly six months, and that IntelGenx's
partner Edgemont Pharmaceuticals appears to have dealt with most of the
initial snags that impacted the launch of the drug. Accordingly, therefore,
we anticipate meaningful acceleration in Forfivo™ prescription volumes in
the coming months. While we do not expect the drug to become a massive
seller, we note that even a relatively modest revenue base would likely have
substantial impact on IntelGenx's bottom line, and should be sufficient to
drive the company towards profitability. We note that IntelGenx continues to
exhibit a cost-effective operational approach, burning roughly $2mm or less
per year. We reiterate our Buy rating and 18-month price target of $3.00 per
share on IGXT.
¦
Rizatriptan 505(b)(2) Application Filed. In March 2013, IntelGenx
reported that it had filed for approval of an oral film-based proprietary
formulation of rizatriptan, a well-known anti-migraine drug belonging
to the triptan class. Rizatriptan, which was originally developed and
commercialized by Merck & Co. (MRK/NYSE, Not Rated) under the trade
name Maxalt, had sales of $638mm in 2012. The patent protection on Maxalt
has now expired. We believe that, even in the face of generic competition,
it should be possible for IntelGenx's oral film formulation to eke out a solid
niche in the migraine market, particularly as the company's delivery approach
provides substantial advantages from an absorbability perspective.
¦
Management Transition Announced. IntelGenx recently appointed Dr.
Rajiv Khosla, a widely-respected industry veteran who previously spent
several years at Biovail Corporation - now Valeant Pharmaceuticals
International (VRX/NYSE, Buy) - as Chief Scientific Officer and Chief
Operating Officer. Dr. Khosla is also slated to assume the post of CEO
effective January 2014. Horst Zerbe, the company's founder and current CEO,
is expected to stay on as Chairman of the Board of Directors and is slated to
continue to provide expertise on formulation, drug manufacturing and R&D.
From our perspective, the appointment of Dr. Khosla is a solid step forward
for IntelGenx and should enable the firm to operate more aggressively from
an out-licensing and partnership standpoint.
¦
Additional Catalysts Expected Near-Term. We believe that 2013 is likely
to be a watershed year for IntelGenx because this is the first time that
the company is in position to reap rewards from a marketed product -
Forfivo - which is in full ramp mode, while simultaneously filing other
drug candidates for approval with the FDA. In our view, even one or two
regulatory submissions should catch the eye of discerning investors, the
majority of whom we continue to believe are unaware of the potential inherent
in IntelGenx's diversified product candidate portfolio and capital-efficient
business model.

Follow Link For The Full Article:http://slidesha.re/180C311

Pan American Fertilizer (CNSX: PAF) appoints new President

VANCOUVER, BRITISH COLUMBIA, April 22, 2013 – Pan American Fertilizer Corp., (CNSX: PAF) (“Pan American” or the “Company”) announced today that it has appointed Mr. Scott Walters as President of the Company, effective immediately. Randy Wright will remain Chairman of the Board and Chief Executive Officer.

On his appointment, Scott Walters stated, “I look forward to working with Randy and our team on growing revenue through continued sales growth and expanding distribution to our rapidly developing customer base in South America. We will continue our focus of delivering key agricultural products and leveraging our team’s operational expertise with the goal of providing shareholders increased value and profitability.”



A financial executive, with over eighteen years international experience; creating, building and selling successful businesses in the financial and resource sector, Scott Walters has spent the majority of his career investing in and financing the natural resource space with a focus on gold, silver, uranium and agri-minerals. He is well versed in all types of investment banking transactions and over the last few years primarily focused on public and private equity and debt offerings; exclusive sale assignments, strategic advisory assignments, RTO’s and IPO’s. Investment targets have been in the Americas, Europe, Central Asia, Australasia and several African nations. Previously Managing Partner and Founder of several successful companies, Scott has extensive experience managing people and projects in the resource sector.



"I am delighted to welcome Scott Walters to the Pan American team, and am pleased he will be undertaking the role of President,” said Randy Wright, Chairman and CEO of the Company. “Scott has been an active strategic advisor in the agri-consulting sector for many years and our Company can only benefit from his insight and expertise. I am confident that under his strategic guidance and leadership, Pan American will continue to grow its market share and is on the right path to becoming a major player in the fertilizer and industrial mineral market.”

Pan American Fertilizer (CNSX: PAF) New Director and Officer Appointments



Source: http://bit.ly/100fZMI



VANCOUVER, BRITISH COLUMBIA, March 20, 2013 - Pan American Fertilizer Corp., (CNSX: PAF) (“Pan American” or the “Company”) today announced that it has appointed two new Directors to its Board, and appointed one new Officer of the company.

"I am delighted to welcome Ignacio Randle and Greg Reimer to Pan American’s Board of Directors, and am pleased to announce the Officer appointment of Sukhprit Sajan as Vice President - Finance,” said Randy Wright, Chairman, President and CEO of the Company. “As we continue to grow and expand our market share, our company will benefit from their depth of knowledge and diversity in experience.”

Ignacio J Randle is a partner at the law firm Estudio Randle in Buenos Aires, Argentina, advising domestic and foreign clients in international business transactions, transnational investment, and M&A’s with emphasis in energy and natural resources projects. He is recognized throughout the world, as a leader in his field and his practice covers mining exploration, development and production; including title review, due diligence of permit, engineering, construction, operation, option, lease, royalty and purchase and joint-venture agreements, as well as mining-related compliance, litigation, tax, regulatory, private and public financing, employment, corporate, community and environmental health and safety matters. He received his law degree from the Catholic University of Argentina in 1986 and his Master in Laws (LLM) degree from the University of Chicago Law School in 1990. He practiced as a foreign attorney with Baker & Botts in Houston, Texas and Washington, DC, and with McDermott, Will & Emery in Chicago, Illinois. He has served as a Board Member for Oroplata S.A. (Goldcorp.) - June 2011 - December 2011; currently serves as Alternative board of director member of Goldcorp Exploraciones de Argentina S.A. - January 2012 to present; and serves as Trustee, Rocky Mountain Mineral Law Foundation - 2011 to Present.

Gregory (Greg) Reimer served 26 years in the BC Public Service prior to being appointed Executive Vice-President of BC Hydro's Transmission & Distribution business group in June 2010. Mr. Reimer has extensive operational experience and demonstrated strong leadership. He is responsible for overseeing significant capital infrastructure initiatives that involve the expansion, upgrading and maintenance of the province's transmission and distribution systems. A Certified General Accountant by profession, Mr. Reimer held senior leadership positions in the public sector, including Deputy Minister of Provincial Revenue and, most recently, Deputy Minister of Energy, Mines and Petroleum Resources. In this role, he led the development of the 2007 BC Energy Plan and the 2010 Clean Energy Act.

Sukhprit Sajan, CGA, has several years experience working in rapidly growing companies, and has conducted business throughout North and Central America, the Caribbean, United Kingdom and Europe.
Over the course of his career Sukhprit has been retained in a variety of roles, undertaking a broad range of fiduciary and financial responsibilities, including: cash management and treasury functions, implementation of financial systems and controls, enhancement of policies and procedures, financial and management reporting, and team development.

Pan American Board members are appointed, or re-elected, on an annual basis. At the recently held Annual General Meeting (AGM); Mr. Ignacio Randle, Mr. Greg Reimer, Mr. Ben Wendland, Mr. Kurt Loewen and Mr. Randy Wright were appointed to the Pan American Board of Directors.



About Pan American Fertilizer Corp.
Pan American is a Canadian company dedicated to providing fertilizer to growing global markets specifically in South and Central America. The company is focused on the extraction of a specific type of fertilizer called calcium sulphate (also referred to as “Agricultural Gypsum”) currently in Argentina. To ensure long term development and increase shareholder value, Pan American currently plans to significantly expand its current operational objectives while expanding its asset base by acquiring additional calcium sulphate and other fertilizer related assets and by expanding its markets to neighbouring countries with Argentina.

When used as a fertilizer and as a soil remediator, calcium sulphate is a soft sulphate mineral composed of calcium sulphate dihydrate which is extremely rich in sulphur and calcium. When dissolved in water, the mineral becomes calcium and sulphate sulphur ions, both of which are required nutrients for plants. Calcium sulphate plays a vital role in establishing and maintaining good chemical balance in soil, water and plants, specifically with healthy root development. Ultimately, calcium sulphate increases overall crop quality and yields. For more information please look at our website www.PAFertilzer.com

Interested in investing money online? The stock market can be a fatal addiction for anyone; It is perhaps the most volatile thing on earth, it’s like a gamble. The rolling money will lure you in and then suddenly one day you may lose everything. This is a kind of investment where you can get high rewards, but with high risks. If you are a regular player in the stock market you always have to be on your guard and develop your intuition to a point where you can feel the dipping and rising pulse of the market and invest accordingly. Now, there are various tools available on the net with which you can play safe – reduce the risk and increase the chances of success.

A stock market discussion forum is a tool, which will influence your stock or share market investment. It is a platform that attracts all kinds of investors – from old school investors, to young ones who are eager to make a quick buck voice their opinions in this forum. The best thing about these discussion forums is that you get different perspectives on which shares to buy, sell or keep for the short and long run. The best way to know about the market is to talk to others because it is important to know the background when you are investing in shares. Apart from different opinions, these discussion forums also feature the latest news and speculation techniques of the stock market.

“Message boards, discussion forums and chat rooms are the most effective way to get unbiased help from other online investors,” says Robert James from Viral Stocks. “I find that a simple introduction, a few questions and sharing a couple items is the best way to join a discussion.”

You may not be a fanatic follower of the stock you have invested in but, from the views and comments posted in the discussion forum you’ll have better knowledge of the upturns and downturns of the stock purchased or planning to purchase. It is surprising how many times the stock prices fluctuate due to the comments and views posted in these discussion forums. It is clear that a stock market discussion forum has a definite influence on buyer and seller behavior, which in turn affects the price of the stock.

Do these discussion forums post news only related to the fluctuations in stock price? The answer is: of course not. You can get a wide array of news from lawsuits, which may impact a particular stock and information on the new entrants in the market. If you have had a bad trading day discussion forums are places where you can regain your confidence. Stock market discussions allow you to form a clear investor decision based on cumulative opinions and diverse views.

Sometimes these discussion forums are also sometimes equipped with Live Chat applications. With the help of these you can get some real time advice, tips of stocks, shares, and investing in stocks online. Stock trading is one of the oldest forms of making money but then there is a high risk of losing all your investment. Stock market discussion forums will help you to stay ahead and updated on the latest news in the market.

A social environment within a platform, such as the Viral Stocks PRO Dashboard, allows users to chat, share their picks and opinions and creates a community atmosphere. With experienced professionals such as Robert James in these rooms ready to guide you with online trading, you’ll be sure to grow as an investor.



Viral Stocks PRO: http://viralstocks.com/pro/

IntelGenx Reports 2012 Annual Results and Provides Operational Update


NDA for Rizatriptan Anti-Migraine VersaFilm(TM) to be filed by the end of this month

Saint Laurent, Quebec--(Newsfile Corp. - March 18, 2013) - IntelGenx Corp. (TSXV: IGX) (OTCQX: IGXT) (the "Company") today announced financial results for its fiscal year ended December 31, 2012 and provided an update on operational developments.

"We ended 2012 with cash exceeding $2 million, no debt, and our first FDA-approved product, Forfivo XL, having been successfully launched in the USA by Edgemont Pharmaceuticals," stated Dr. Horst G. Zerbe, President and CEO of IntelGenx. "As we enter 2013, we have received payment of the $1.0 million milestone invoiced to Edgemont at the end of the fourth quarter of 2012, and we look forward to receiving royalty income from Forfivo XL whilst we pursue licensing opportunities for the rest of the world. We will also continue to focus our attention on achieving FDA approval of the remaining products in our pipeline, with a 505(b)(2) NDA submission for our anti-migraine VersaFilm product on track to be filed by the end of March 2013, as previously disclosed."

Corporate Development Update

Anti-migraine VersaFilm™ (rizatriptan)

In May 2012, we announced the completion of the pivotal bioequivalence study for a novel oral thin-film formulation of Rizatriptan, the active drug in Maxalt-MLT® orally disintegrating tablets. The study results indicate that the product is safe, and that the 90% confidence intervals of the three relevant parameters Cmax, AUC(0-t) and AUC(0-infinity) are well within the acceptance range for bioequivalency.

In November 2012 we announced the successful conclusion of a pre-New Drug Application ("NDA") meeting with the U.S. Food and Drug Administration related to our VersaFilm™ formulation of Rizatriptan. The purpose of the meeting was to receive confirmation from FDA regarding the adequacy of the clinical, non-clinical and CMC data for our proposed 505(b)(2) NDA submission, which we are on track to file by the end of the first quarter of 2013.

Maxalt-MLT® is a leading branded anti-migraine product manufactured by Merck & Co. Our thin-film formulation of Rizatriptan has been developed in accordance with the co-development and commercialization agreement with RedHill Biopharma Ltd. using IntelGenx' proprietary immediate release "VersaFilm™" drug delivery technology.

Erectile Dysfunction VersaFilm™ (tadalafil)

Subsequent to the end of the year, in February 2013 we successfully completed a pilot bioequivalence study on our erectile dysfunction VersaFilm™ product. In a previous study, we had already demonstrated that we are able to formulate a bioequivalent product. In the recently completed study, we showed that we were additionally able to develop a faster formulation with a significantly shorter Tmax which will address the need for a faster tadalafil product.

Development and Commercialization Agreement with Par Pharmaceutical, Inc.

In December 2011 we announced the execution of a co-development and commercialization agreement with Par Pharmaceutical, Inc. ("Par") for a new product utilizing one of our proprietary oral drug delivery platform technologies. This program continues to make progress. For commercial reasons, and in order to protect both Par’s and IntelGenx’ competitive advantage, the agreement stipulates that all information pertaining to the product, together with financial terms of the agreement, are to remain confidential.

Antihypertensive VersaTab™ product

We recently completed a pilot bioequivalence study for our antihypertensive project, INT0001, a generic equivalent to a major cardiovascular product, using our proprietary VersaTab™ delivery technology. We continue to make progress with the project and, together with our strategic partner, Dava Pharmaceuticals Inc., are working diligently towards the filing of an ANDA with the FDA.

Financial Results:

The cash balance of $2.1 million as at December 31, 2012 compares with cash of $3.5 million at December 31, 2011. Net funds used in operations totaled $1.6 million in 2012, compared with net funds used of $2.3 million in 2011, and funds used in investing activities totaled $0.3 million and $0.2 million in 2012 and 2011 respectively. Funds generated from financing activities were $0.4 million in 2012 compared with $4.8 million in 2011, including $3.2 million from private placements completed in June 2011.

Accounts receivable of $1.3 million as at December 31, 2012 (December 31, 2011 - $0.3 million) includes an amount of $1.0 million related to the launch of Forfivo XL™ that was invoiced to Edgemont Pharmaceuticals in the fourth quarter of 2012. Payment against the invoice was received in February 2013.

Revenue improved from $0.4 million in fiscal 2011 to $1.2 million in 2012, primarily due to the milestone payment of $1.0 million invoiced to Edgemont Pharmaceuticals for the launch of Forfivo XL™ in the fourth quarter of 2012.

Total expenses increased from $2.9 million in fiscal 2011 to $3.5 million in 2012. The increase is primarily attributable to additional R&D expenditure of $0.3 million related to costs associated with the technical transfer of activities in preparation of the manufacture of Forfivo XL™ and a Product Fee for Forfivo XL™ payable to the FDA.

The net loss decreased from $2.5 million in fiscal 2011 to a loss of $2.3 million in 2012, and the loss per share decreased from $0.05 per share in 2011 to $0.04 per share in 2012.

About IntelGenx:

IntelGenx is a drug delivery company focused on the development of oral controlled-release products as well as novel rapidly disintegrating delivery systems. IntelGenx uses its unique multiple layer delivery system to provide zero-order release of active drugs in the gastrointestinal tract. IntelGenx has also developed novel delivery technologies for the rapid delivery of pharmaceutically active substances in the oral cavity based on its experience with rapidly disintegrating films. IntelGenx' development pipeline includes products for the treatment of severe depression, hypertension, erectile dysfunction, benign prostatic hyperplasia, migraine, insomnia, idiopathic pulmonary fibrosis, allergies and pain management. More information is available about the company at Www.Intelgenx.Com.

Forward Looking Statements:

This document may contain forward-looking information about IntelGenx' operating results and business prospects that involve substantial risks and uncertainties. Statements that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, but are not limited to, statements about IntelGenx' plans, objectives, expectations, strategies, intentions or other characterizations of future events or circumstances and are generally identified by the words "may," "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates," "could," "would," and similar expressions. All forward looking statements are expressly qualified in their entirety by this cautionary statement. Because these forward-looking statements are subject to a number of risks and uncertainties, IntelGenx' actual results could differ materially from those expressed or implied by these forward looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed under the heading "Risk Factors" in IntelGenx' annual report on Form 10-K for the fiscal year ended December 31, 2011, filed with the United States Securities and Exchange Commission and available at Www.Sec.Gov, and also filed with Canadian securities regulatory authorities and Www.Sedar.Com. IntelGenx assumes no obligation to update any such forward-looking statements.

Source: bit.ly/YkHbr8

IntelGenx to Present at Roth Capital Partners 25th Annual Growth Stock Conference


Saint Laurent, Quebec--(Newsfile Corp. - March 18, 2013) - IntelGenx Corp. (TSXV: IGX) (OTCQX: IGXT) (the "Company") today announced that it will be presenting at the Roth Capital Partners 25th Annual Growth Stock Conference at the Ritz-Carlton Hotel in Dana Point, California.

The presentation at the Roth conference is scheduled for 11:00 am PDT (2:00 pm EDT) on Wednesday March 20, 2013. The presentation will be webcast, and a recording of the webcast will be available on IntelGenx' website shortly thereafter.


Read the full release: http://bit.ly/ZE0KsZ

Video News Release


Lomiko Signs Alliance with Graphene Labratories Inc. to Build Business Opportunities

News group Viral News puts out the press release in video format.

Watch the video: http://goo.gl/QwHxx

A Guide on Online Investment Communities

As the global economy is growing bigger and expanding throughout the world more and more people are investing their money expecting high returns. Who doesn’t want to see his or her money grow? The only solution to grow your money is through investing. The term ‘investment’ is no longer financial jargon but a very common word these days. With the sudden increase in investors, many online investors’ communities are developing helpful resources. Being a citizen of one country still allows you to easily invest in any other country.

What is an online investor community? In simple words, an online investor community is a platform where investors belonging to different communities come together and share their views. These forums discuss various issues related to trade and investments. With tools like blogs and chat investors are also free to discuss various topics regarding investment and the current market scenario in these forums. This is usually beneficial for people who do not have any experience or prior knowledge for investing. These online investor communities’ help you gather crucial information about how to invest and the best solutions available in the market.

To reap the real benefits of an online investor community, one has to be very careful while choosing one. Make sure to choose a community that is renowned and has been providing genuine information related to this field for a good period of time. It should be a comfortable online environment where you get to interact with investors and share your views with ease. This is one of the best ways to learn and gather experience about investments. Here, collaboration is key for success.

Find a suitable online investor community with the help of search engines and research on social media. Check their credentials thoroughly before becoming a member. As a member you will be able to get real-time updates on investments and will be able to follow like-minded investors. In addition to this members can view and gauge real-time sentiments of the investment market and act accordingly. Veterans opine that these play an important role in shaping the behavior of the investors and their investment objectives.

What else can you find in these online investor communities that can prove beneficial to you? You will get the latest news about the investment market, free tips on how to invest better, future investment trends, and what types of return you can get based on your investment objectives.

Need more education on the market? Click here to read the rest of our educational series. Feel like you know it all? Start following your favorite tickers in real-time, chat with a community of traders like yourself, attend strategic trading webinars and trade side by side with the best using the Viral Stocks Pro trading dashboard: www.viralstocks.com/pro/

What is the TSX Venture Exchange? What is its purpose? What kind of companies are listed on the exchange? How does the TSX Venture perform, should I invest in it? Do you ever find yourself asking questions like these, or maybe you’re just looking for some fun and interesting facts about the TSX Venture Exchange. Whatever the case, prepare to inform and educate yourself.


Great blog post educating on the TSX Venture. Here's the link: http://viralstocks.com/tsx-venture-exchange-did-you-know/



Post:

Some Interesting Facts about the TSX Venture

- The TSX Venture was originally formed from the merger of the Vancouver Stock Exchange (VSE) and Alberta Stock Exchange (ASE) and wasn’t named the Canadian Venture Exchange, or CDNX until 2001 once the TMX bought it?

- The Venture is used as a springboard, allowing companies to get financing and grow so they can eventually migrate to theTSX.

- The TSX Venture has a total of approximately 2,300 companies

- Companies listed on the TSX Venture can be identified by having the letter ‘V’ after the symbol. For example: ABC.V

- The Venture is owned and operated by the TMX Group

- The materials sector makes up 48.07% of the TSX Venture. Energy makes up 40.60%, Financials make up 2.72%, health care chips in at 2.09%, industrials at 2.08% then information technology, consumer discretionary, utilities and consumer staples all coming in under 2%

- A symbol previously used by other issuers cannot be reassigned for 53 weeks.

- It takes a total of between 3-6 months to get listed on the TSX Venture with 15 different events having to take place before the listing is final

- There are 4 different ways to take a company public on the Venture exchange:
o Initial Public Offering
o Reverse Takeover
o Capital Pool Company
o Direct Listing

- An ‘Advanced Company Venture’ is an issuer listed on the Venture Exchange that has significant financial resources and satisfies the tier 1 listing standards. A tier 1 issuer benefits from a more favorable regulatory environment and increased opportunity for participation by institutional investors.

- There are much fewer advanced or tier 1 companies on the TSX Venture than tier 2 companies.

- A Capital Pool Company (CPC) is a new company trading on the TSX Venture that has no commercial operations or assets except for cash. CPC’s use their cash holdings to evaluate assets to acquire in a qualifying transaction. This must be completed within 24 months of the listing. After the qualifying transaction is complete, the company can be listed as a standard Tier 1 or 2 issuer on the TSX Venture. CPC’s can be identified by the ‘P’ after their ticker symbol.

- The difference between a tier 1 and 2 issuer on the TSX.V is the listing criteria. A tier 1 issuer is required more net tangible assets and pre-tax earnings than a tier 2 company. The exact numbers are based on the industry the company is in.

TSX Venture S&P Index Specific

- The S&P/TSX Venture Composite Index is a broad market capitalization-based index which is designed to measure the performance of securities listed on the TSX Venture Exchange, Canada’s primary venture equity market.

- The S&P/TSX Venture Composite Index has a 409 constituents

- The average constituent market cap is 0.058 billion

- The largest constituent market cap is 1.843 billion

- The smallest constituent market cap is 0.008 billion

- The market cap of the index is 23.72 billion

- Securities must be incorporated under Canadian federal, provincial, or territorial jurisdictions and listed on the TSX Venture Exchange.

- Market Capitalization: At the end of every calendar quarter, a security must have a relative weight of at least 0.05% of the total capitalization of the S&P/TSX Venture Composite Index to continue to be included in the index, after taking into consideration all share changes, additions and deletions.

- Eligible Securities: Shares other than those of capital pools and NEX issuers, preferred shares, exchangeable shares, warrants, rights, US$ denominated securities, inactive or suspended issuers and other financial instruments the Index Committee deems inappropriate are not eligible for inclusion in the index. Installment receipts are not eligible for inclusion in the index, but can be used in lieu of common share trading history.

- Shares Outstanding: All classes of common shares (excluding inactive issuers) – those issued and outstanding shares which represent the residual equity of the earnings in the company — are eligible for inclusion in the index. The number of shares of a company used for the calculation of the index will be the total shares issued and outstanding less shares held in escrow, as determined by the TSX Venture Exchange.

Need more education on the market? Click here to read the rest of our educational series. Feel like you know it all? Start following your favorite tickers in real-time, chat with a community of traders like yourself, attend strategic trading webinars and trade side by side with the best using the Viral Stocks Pro trading dashboard: http://viralstocks.com/

Calyx Announces Prominent Climate Change Attorney Appointed as Advisor

VANCOUVER, BRITISH COLUMBIA--(Marketwire - Feb. 26, 2013) - Calyx Bio-Ventures Inc. (TSX VENTURE:CYX) is pleased to announce the appointment of Gray Taylor, identified in 2011 as the leading climate change lawyer in Canada, as an advisor to the company.

Taylor is presently co-leader and counsel of Bennett Jones' Climate Change and Emission Trading practice. He focuses on climate change and related corporate issues affecting businesses in Canada and abroad. Taylor has acted on a number of complex transactions, including the representation of the largest private sector participants in the World Bank (US) $1-billion Umbrella Carbon Fund transaction.

Taylor is heavily involved with emissions trading transactions involving Emission Reduction Purchase Agreements and related financing and transactional documents for a broad range of Kyoto Protocol (CDM and JI), Alberta and other Canadian regulatory deals. He's also involved with North American and international voluntary carbon deals, and advises on corporate governance and climate change business planning issues.

Past Chair of the National Environmental, Energy and Resources Law Section of the Canadian Bar Association, Taylor is a director of the International Emissions Trading Association and the co-chair of its Canadian Working Group.

"As a leading climate change lawyer, Gray Taylor brings insight and a wealth of experience to our table," said Hugh Notman, President and CEO of Calyx. "His guidance will be very valuable with our majority-owned subsidiary, Agrisoma Biosciences Inc., and its efforts to commercialize its proprietary oilseed crop for biofuel production. His deep understanding of climate change initiatives will be extremely helpful as we create biofuel initiatives and accelerate our company's development."

"It is a privilege to be associated with Calyx and its biofuels business," said Taylor. "Harnessing the ecosystem to reduce greenhouse gas emissions is a critical part of achieving a low-carbon future. I believe Calyx can play an important role in those efforts."

About Calyx

Calyx Bio-Ventures Inc. trades on the TSX Venture Exchange under the symbol "CYX" and owns a majority position in Agrisoma Biosciences Inc. Agrisoma is a private agricultural biotechnology company that uses a proprietary Engineered Trait Loci (ETL) technology licensed from Calyx to commercialize a suite of industry-leading oil quality and crop improvement traits for use in energy feedstock crops. Agrisoma is currently commercializing Resonance™ carinata, a non-food oilseed crop that is well suited for cultivation on semi-arid lands. For further information about Calyx, its technology, collaborations and partnerships, please visit www.calyxbio.com. For more information about Agrisoma, visit www.agrisoma.com.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information:
Calyx Bio-Ventures Inc.
W. Hugh Notman
President & CEO
604-689-2495
hnotman@calyxbio.com


Calyx Bio-Ventures Inc.
Keir Reynolds
Investor Relations
778-998-9242
kreynolds@calyxbio.com
www.calyxbio.com

Pinnacle Digest features Calyx - Our Big Bet of 2013: Calyx Bio-Ventures (CYX:TSXV)

Stock is up 12% With great volume..keep watch for it to break resistance.

Excerpt from the article:

Our new client and Featured Company, Calyx Bio-Ventures (CYX:TSXV), will undoubtedly represent the largest trade we make in 2013. Calyx owns a majority interest in a game changing renewable energy company that was recently a part of aviation history. When it comes to renewable energy investing, a sector with which we have been involved for many years, a company must have what we refer to as the 5 M's: Mission, Mandates, Management, Money and a low Market Cap.

Calyx Bio-Ventures' mission is a remarkable one and that's why we are introducing it to you. The company's operating subsidiary, in partnership with the government of Canada, Chevron Lummus Global and Applied Research Associates, recently made world history in what Popular Science Magazine referred to as one of "The Big Science Stories of 2012".

Read the full article: http://bit.ly/CalyxPinnacle

Pan American Fertilizer (CNSX: PAF) Chairman Letter: Re-cap 2012, a look at 2013.



VANCOUVER, BRITISH COLUMBIA, February 15, 2013 - Pan American Fertilizer Corp., (CNSX: PAF) (“Pan American” or the “Company”) releases the following Corporate Update to its shareholders, from the Chairman; Randy Wright.


Source: http://bit.ly/VmbS0n


Dear Shareholder,


It gives me great pleasure to be able to provide you with an update on the progress and developments of Pan American Fertilizer Corp. Since our establishment in May 2012, we have made significant progress on our Santiago Del Estero Agricultural Gypsum project and I am pleased to confirm that the Company has successfully met the milestones that were established for 2012.


Highlights for 2012 include:


Official Mining Certificate obtained;

Successful testing of our extraction process;

Execution of 24 hour extraction cycle;

Agreement established with nation-wide distribution company (Mamasu);

Successful execution of end-to-end sales cycle;

12,000 tonnes of Calcium Sulphate (granular and powder) extracted; and

USD$490,000.00 received in revenue (from actual sales completed during our testing phase).

These achievements are significant as 2012 was a testing, building and development year for us. In 2013 our focus shifts to the following areas; growing our sales channels, increasing our extraction capacity and expanding distribution into other countries. It is our expectation that we will experience continuous organic growth this year, and our confidence in meeting our expectations is demonstrated in the milestones we have set for 2013.


Primary Milestone (2013):


Sales of 100,000 tonnes

Late last year, Pan American disclosed that the Company had successfully closed a purchase order with Paraguayan company; Agro Industrial (“Agro”), for up to 48,000 tonnes (announced Nov 16, 2012), at a price of US$97.81 per tonne, to be executed and delivered in 2013. We are pleased to announce that the Company has met, and continues to meet, the delivery milestones under this agreement.


In addition to the sales to Agro, we will continue to distribute our high quality product throughout Argentina, via our Mamasu distributor (per the arrangement with Mamasu announced July 30, 2012). We are pleased to report that through this arrangement, we have shipped approximately 10,000 tonnes.


As we continue to mature, and in alignment with our core business model of increasing cash-flow by extracting and selling fertilizer related products, once primary growth milestones are reached, it is the Company’s medium to long term intended goal, that subject to legal and contractual restrictions, we will be able to declare a dividend to shareholders.


Actual declared dividends are subject to the discretion of the Company’s Board of Directors and may vary from the intentions stated depending on, among other things, the Company’s earnings, financial requirements and other conditions existing at such future time.


Our strategy remains based on the simple principal of supplying the highest quality product available to a continually growing, robust market. As we move forward and meet both our extraction and sales milestones, our anticipated revenue stream will allow us to also pursue value added transactions with local Argentinean and international partners. We will continue to remain open to new opportunities that will leverage our current position and enable us to meet our long-term vision of becoming a major global fertilizer supplier.


Your Board of Directors and management team remain dedicated to increasing shareholder value, and we continue to be motivated by the prospects of the Company. I would like to personally thank each of you, and will work to ensure your trust is maintained as Pan American grows.


Sincerely,


Randy Wright

Chairman, President and CEO

Video of yesterdays Q&A With Gary Schellenberg?

TNR Gold Corp. (TSX.V - TNR) CEO Gary Schellenberg sits down for a Q&A interview on the Settlement of the Los Azules Copper Project Lawsuit


Link:

News Release: Pan American Fertilizer Corp. (CNSX: PAF) Announces Closing Of Non-Brokered Private Placement



VANCOUVER, BRITISH COLUMBIA, January 31, 2013 - Pan American Fertilizer Corp. (CNSX: PAF) (“Pan American” or the "Company") announces that it has closed a portion of the non-brokered private placement (the “Offering”) as previously announced on October 24, 2012 and issued 240,000 units (“Units”) at a price of $0.25 per Unit for gross proceeds of $60,000. Each Unit consists of one common share of the Company (a “Share”) and one common share purchase warrant (a “Warrant”). Each Warrant entitles the holder thereof to purchase one additional Share at a price of $0.40 per Share at any time until January 31, 2018.



In connection with the Offering, the Company has paid Jordan Capital Market Inc. (the “Finder”) a cash commission in the amount of $4,800, being 8% of the aggregate proceeds from the sale of Units to purchasers introduced by the Finder. The Company has also issued non-transferrable Warrants to the Finder to acquire up to 19,200 Shares, being 8% of the number of Units sold under the Offering to purchasers introduced by the Finder, exercisable at $0.40 per Share until January 31, 2018.



The net proceeds from the Offering are to be used for working capital purposes. All securities issued in connection with the Offering are subject to a four month statutory hold period expiring on June 1, 2013.



About Pan American Fertilizer Corp.



Pan American is a Canadian company dedicated to providing fertilizer to a growing global market. The company is focused on the extraction of a specific type of fertilizer called calcium sulphate (also referred to as “Agricultural Gypsum”). To ensure long term development and increase shareholder value, Pan American currently plans to significantly expand its current operational objectives while expanding its asset base by acquiring additional calcium sulphate and other fertilizer related assets.



When used as a fertilizer and as a soil remediator, calcium sulphate is a soft sulfate mineral composed of calcium sulfate dihydrate which is extremely rich in sulphur and calcium. When dissolved in water, the mineral becomes calcium and sulphate sulphur ions, both of which are required nutrients for plants. Calcium sulphate plays a vital role in establishing and maintaining good chemical balance in soil, water and plants, specifically with healthy root development. Ultimately, calcium sulphate increases overall crop quality and yields.



On behalf of the board of directors of Pan American Fertilizer Corp.



“Randy Wright”



Randy Wright

President and CEO



FOR MORE INFORMATION, PLEASE CONTACT:



Arwen Reynolds

areynolds@pafertilizer.com

(604) 638-3480

Jay Taylor lists Southern Silver Exploration as a Buy Recommendation for 2013

Southern Silver Exploration was one of the few companies Jay Taylor has on his buy list for 2013. In the video, Jay analyzes a number of junior mining companies while the CEOs of each company give a little of their own insight on the company and the future of the market.

Watch the video:

Jay Taylor lists Brazil Resources as a Buy Recommendation for 2013

Brazil Resources Inc. was one of the few companies Jay Taylor has on his buy list for 2013. In the video, Jay analyzes a number of junior mining companies while the CEOs of each company give a little of their own insight on the company and the future of the market.

Watch the video:

Jay Taylor lists Eurasian Minerals as a Buy Recommendation for 2013

Eurasian Minerals was one of the few companies Jay Taylor has on his buy list for 2013. In the video, Jay analyzes a number of junior mining companies while the CEOs of each company give a little of their own insight on the company and the future of the market.

Watch the video:

Jay Taylor lists Almaden Minerals as a Buy Recommendation for 2013

Almaden Minerals was one of the few companies Jay Taylor has on his buy list for 2013. In the video, Jay analyzes a number of junior mining companies while the CEOs of each company give a little of their own insight on the company and the future of the market.

Watch the video:

Jay Taylor lists Miranda Gold Corp as a Buy Recommendation for 2013

Miranda Gold Corp was one of the few companies Jay Taylor has on his buy list for 2013. In the video, Jay analyzes a number of junior mining companies while the CEOs of each company give a little of their own insight on the company and the future of the market.

Watch the video:

Cambridge House Investment Conference Coverage 2013 - Vancouver

Exclusive coverage of the event, investor opinions and outlooks for the future and 1 on 1 interviews with Peter Schiff, Jay Taylor and other event speakers.

Dale Paruk of NioGold is also interviewd in this video.

Watch the video:

NioGold Begins Program On Marban Block Property

Source: http://bit.ly/VZX05r

Val-d'Or, Quebec -- NioGold Mining Corporation (TSX-V: NOX) (OTCQX: NOXGF) ("NioGold") is pleased to announce that it has commenced a $1.6M exploration program on its Marban Block property, currently under option to Aurizon, to drill the Kierens and Norlartic deposits and the North zone.

The Marban Block property contains the Kierens, Norlartic and Marban deposits which have a collective resource estimate of 1.56 M ounces (28.5 millions of tonnes at 1.70 g/t) in the measured and indicated categories and 0.51 M ounces (9.6 millions of tonnes at 1.66 g/t) in the inferred category (see news release of September 7, 2012).

The drilling at Kierens and Norlartic will explore the open pit potential of these two deposits, further test their extensions in all directions, and attempt to convert the existing inferred resources to a higher category. Both require winter drilling programs due to the need to build ice bridges on the Keriens Creek, located north-east of the Kierens-Norlartic trend, in order to drill the upper part of the deposits.

The North zone is located about 200m northeast and parallel to the Norlartic zone, and consists of three sub-zones named A (north-easternmost), B (centermost) and C (south-westernmost). The drilling at the North zone will investigate the potential for a resource estimate and possible open pit scenario.

Due to the timing requirements for winter drilling, and in light of Aurizon's ongoing review of the Phase II data, Niogold has agreed to fund the exploration program at this time. The parties have further agreed, however, that upon Aurizon's decision to proceed with the Phase III program, Aurizon will immediately reimburse Niogold for the costs of the exploration program and such amount will then be applied to Aurizon's earn-in requirement.

Aurizon Option

Aurizon can earn up to a 65% interest the Marban Block property under the terms of an option and joint venture agreement dated July 5, 2010, between NioGold and Aurizon. The initial 50% interest can be earned by incurring expenditures of $20 million over three years, completing an updated NI 43-101 compliant mineral resource estimate, and by making a resource payment for 50% of the total gold ounces defined by the mineral resource estimate. NioGold remains the project operator during the initial earn-in period (see news release dated July 6, 2010).

Technical Info, Qualified Persons and QA/QC

The drilling programs are conducted under the supervision of Yan Ducharme, M.Sc., P.Geo. (OGQ), the NioGold Vice president of exploration and a Qualified Person as defined by National Instrument 43-101. The news released was prepared by Mr. Ducharme.

NioGold Mining Corporation – « On Canada’s Golden Highway »

NioGold Mining Corporation is a mineral exploration company focused on gold. The Company’s flagship projects are located in the Cadillac - Malartic - Val-d’Or region of the prolific Abitibi gold mining district Quebec. The Cadillac, Malartic and Val-d’Or mining camps have produced over 45 million ounces of gold since the 1930’s and presently encompasses six producing gold mines including Osisko Mining’s new Canadian Malartic operations. NioGold’s land holdings within the Abitibi presently cover 130 km2 and encompass four former gold producers, namely the Norlartic, Kierens (First Canadian), Marban and Malartic Hygrade mines that collectively produced 640,000 ounces of gold.

NioGold's experienced and qualified technical team are overseeing the advancement of these projects, with current drill programs underway targeting expansion of the resource base.

First Liberty Power Corp. -- Fencemaker Mine Permitting Completed

Source: http://bit.ly/WHXzwP

LAS VEGAS, NV -- (Marketwire) -- 01/15/13 -- First Liberty Power Corp. (OTCQB: FLPC) (the "Company") is pleased to announce that the Antimony property known as Fencemaker is now formally ready for operations. This past August, the Company entered into a Stock Purchase Agreement to acquire a 40.5% interest in Fencemaker and promptly began to build an alliance with Stockpile Reserves LLC ("SRL") to further the process of getting the mine operational. SRL was successful in doing so, and our Operational permits for the Fencemaker mine are in place.

CEO Don Nicholson acknowledged, "First Liberty has reached an important juncture and this is a key development for the Company. With the administrative permit to mine the Fencemaker property being completed, we continue to validate our agenda to grow our mining business activities for 2013." He further stated, "For investors and shareholders, the persistent advancement of the Fencemaker project illustrates the Company's commitment to them as well as strengthens our momentum by increasing our ability to generate revenue in the very near future."

James Vogan, Director of Operation for Stockpile Reserves, the principal partner with First Liberty Power Corp., spoke on the collaboration between the two companies. Mr. Vogan stated, "The operation of the Fencemaker project is steadily moving forward, and the next important objective for the project team is a capital investment to reinforce the mine entrance. Included in this investment will be the reconstruction of several structural supports that will provide safe and dependable access to the mine. Once completed, production runs may begin immediately."

CFO and Treasurer, Mario Beckles, who has substantial financial and accounting experience involving startup operations, together with Mr. Vogan of Stockpile Reserves, are finalizing the assessment of the operations financial statements, including the monthly production rates associated with the business.

Mr. Reynolds, VP Operations, expressed this point, "The entire management team is focused daily on the Fencemaker property, and we are working with our business partners to assist them as we jointly push this project forward. This is a critical detail for the mine's operations to begin. Furthermore, the Company and our partners are doing their diligence daily to get the mine ready for production operations in early 2013."

Antimony is typically refined from stibnite ore and is presently priced at approximately $12,000/MT, making it a high value strategic industrial metal, with stable and growing market demand.

Notice Regarding Forward-Looking Statements

This current report contains "forward-looking statements," as that term is defined in Section 27A of the United States Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future plans of the company, the prospects for our mineral properties, and our ability to raise necessary working capital.

Actual results could differ from those projected in any forward-looking statements due to numerous factors, including the inherent uncertainties associated with mineral exploration and difficulties associated with obtaining financing on acceptable terms. We are not in control of metals prices and these could vary to make development uneconomic. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that the beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that they will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our most recent annual report for our last fiscal year, our quarterly reports, and other periodic reports filed from time-to-time with the SEC.

First video was deleted, here's the new one: http://bit.ly/V8cP58

CEO Matt Manson Interviewed

CEO of Stornoway Diamonds Matt Manson sits down wth Tara Sweder for an exclusive one on one interview. Manson discusses the rarity of diamond mining, the significance of the Renard Diamond Project, the present and future challenges faced in mining for diamonds and his personal experiences in the industry.

Watch the interview: http://bit.ly/RA5jp2

Red Eagle grants options for 2.3 million shares

Mr. Ian Slater reports

STOCK OPTIONS GRANTED

Red Eagle Mining Corp. has granted stock options to buy 2,305,000 shares exercisable at a price of 55 cents until Dec. 6, 2017, to directors, officers, employees and investor relations consultants.

Altima Updates Status of Horizontal Well at Chambers-Ferrier, Alberta and Announces the Grant of Stock Options

Source: http://mwne.ws/TI7tkr

VANCOUVER, BRITISH COLUMBIA--(Marketwire - Dec 5, 2012) -Altima Resources Ltd. (TSX VENTURE:ARH)(ARSLF)(FRANKFURT:AKC) announces that the Operator of the COPOL ET AL HZ CHAMBERS 14-15-41-11 W5M well completed 124.5 hours of production testing on November 26, 2012. The subject well is a confidential New Pool Wildcat (NPW), in which Altima holds a 30% working interest in the well and 2,560 acres of surrounding lands with the operator.

The well tested varying amounts of natural gas and associated high API condensate with no water recovery over the test period. Down-hole pressure recorders were run at the conclusion of the testing operation and will be recovered for analysis in late December. It is anticipated that pipelining will commence in Q1 2013, with production to follow in the first quarter.

On November 15, 2012, the Company announced it had licensed a New Pool Wildcat well at Chambers, Alberta. The well, Altima Chambers 14-35-41-11 W5M, is anticipated to be drilled in Q1 2013 to a depth of 3,065 meters into the Nordegg formation. Altima has a 100% Working Interest in the subject well and offsetting section. The 14-35 well is located approximately 5 kilometers to the north of the COPOL ET AL HZ CHAMBERS 14-15-41-11 W5M well.

The Company''s mostly contiguous land base at Chambers-Ferrier totals twenty (20) sections (12,800 gross acres) with an approximate average working interest of 97.2% in 10 of the 20 sections and varying interests in eight (8) wells.

Richard Switzer, CEO, President and a Certified Professional Geologist, is the Qualified Person under National Instrument 51-101 responsible for preparing and reviewing the data contained in this press release.

Grant of Stock Options:
The Company also announces the grant pursuant to a Fixed Stock Option Plan (the "Fixed Plan"), of options entitling eligible participants to purchase up to 12,000,000 common shares at an exercise price of $0.10 per share for a three year term expiring December 4, 2015. Under the Fixed Plan, the Company has reserved 19,500,000 common shares for issuance, 400,000 of which are currently outstanding. Following this stock option grant a balance of 7,100,000 remains available for future grants.

Pan American Fertilizer (CNSX: PAF) Completion of Shares for Debt Settlement

Source: http://bit.ly/TFLkTV

VANCOUVER, BRITISH COLUMBIA, December 4, 2012 - Pan American Fertilizer Corp., (CNSX: PAF) (“Pan American” or the “Company”) announces that it has entered into a debt settlement agreement on November 30, 2012 (the “Debt Settlement Agreement”) with Randy Wright (“Wright”), the CEO and President of the Company, pursuant to which the Company settled $500,000 of debt owed to Wright by the issuance of 2,000,000 common shares of the Company at a deemed price of $0.25 per share. In addition, the Company has entered into a loan agreement (the “Loan Agreement”) with Wright to extend the term of a loan provided by Wright in the amount of $341,219 for 24 months, payable on December 1, 2014. The Company determined to satisfy its outstanding indebtedness with shares and extension of terms in order to preserve its cash for operations.

The foregoing transactions are “related party transactions”, as such term is defined under Multi-Lateral Instrument 61-101 - Protection of Minority Security Holders in Special Transactions (“MI 61-101”). Pursuant to section 5.5(b) of MI 61-101, the Company is not required to obtain a formal valuation in connection with the transactions as the Company’s common shares are listed for trading on the Canadian National Stock Exchange and none of the Company’s securities are listed or quoted on the Toronto Stock Exchange, the New York Stock Exchange, the American Stock Exchange, the NASDAQ Stock Market, or a stock exchange outside of Canada. Pursuant to section 5.7(a) of MI 61-101, the Company is not required to obtain minority shareholder approval of the transactions as the fair market value of the transactions does not exceed 25% of the Company’s “market capitalization”, as such term is defined under MI 61-101, based on the following:

The aggregate fair market value of the Loan Agreement and the Debt Settlement Agreement is $841,219; and

The current “market capitalization” of the Company, as at October 31, 2012, was $9,441,772, as determined in accordance with section 1.3 of the Ontario Securities Commission Rule 62-504.

The common shares issued to Wright are subject to a hold period in British Columbia expiring on March 31, 2014.

Wright, a director of the Company, declared his interest in the Loan Agreement and the Debt Settlement Agreement to the board of directors of the Company and abstained from voting with respect to the approval of the Loan Agreement and the Debt Settlement Agreement. Upon completion of the transactions, Wright will own 8,262,705 common shares of the Company representing 18.71% of the total number of issued and outstanding common shares of the Company as at the date of this news release.

First Liberty Power Corp Announces Management Team Additions

Source: http://bit.ly/SOlt8S

LAS VEGAS, NV -- (Marketwire) -- 12/04/12 -- First Liberty Power Corp (OTCQB: FLPC) is pleased to announce strategic changes to Upper Management as it continues to execute on its broad strategy to expand.

As First Liberty Power Corp continues to execute on its broad strategy to expand and further develop its exploration and mining portfolio, the current management team believes that strategic personnel changes are needed to accelerate this growth in our US based exploration and mining operations. Therefore, starting immediately, CEO Don Nicholson, is very pleased to announce the additions of Mario Beckles, CPA, as the CFO of the organization and board member, Robert B. Reynolds Jr. will assume additional duties as VP of Operations for First Liberty. Both these individuals bring numerous years of experience as well as professional backgrounds to our corporation.

Mr. Mario Beckles is a senior level accounting and financial management executive with more than 14 years of progressive experience in finance and accounting management involving both startups and global multibillion dollar organizations. He began his career as an auditor with Deloitte and has subsequently held senior level accounting positions with companies such as Tyco International, Claire's Stores Inc. and Investors Bank & Trust. He has continually demonstrated an ability to drive growth initiatives and streamline operations in addition to increasing efficiencies for the organizations he has served. Mr. Beckles also brings strong qualifications in developing and implementing financial controls and processes, financial reporting, and accounting. Mr. Beckles earned a Bachelor's of Science Degree in Accounting and Financial Management from Florida Southern College. He is a Certified Public Accountant (CPA) and a member of the American Institute of Certified Public Accountants.

Mr. Robert B. Reynolds Jr., who currently serves as Chairman of the Company's Board of Directors, will assume the duties of Vice President of Operations. His expanded duties will include oversight of both the mining operation and governmental mining regulations. Mr. Reynolds will assist with the management of our partners conducting operations of the mines and he will manage the media outlets for First Liberty.

CEO Nicholson emphasized that "these two additions to the Management team will greatly assist me in further developing FLPC's prospective properties. They bring to the team a positive 'can do' approach, years of experience and specific strengths that will only help the company as we continue to move forward quickly into the mining operation side of the business." The CEO went on to say, "I am very excited to work with Mario Beckles as he advances our financial side of the business. His CPA background will greatly assist First Liberty as we further stimulate our bottom line and open more opportunities for investors and stock holders. I am very pleased that Mr. Reynolds has accepted an increase role in the company. I'm very confident that this savvy new management team will work together, as we further develop and advance the company's vision of being a truly comprehensive mining operation."

Pan American Fertilizer Corp. (CNSX: PAF) Announces Closing Of 1st Tranche Private Placement

Source: http://bit.ly/SsmhlR

VANCOUVER, BRITISH COLUMBIA, December 3, 2012 - Pan American Fertilizer Corp. (CNSX: PAF) (“Pan American” or the "Company") announces that it has closed the first tranche of a previously announced brokered private placement (the “Offering”) and issued 2,100,000 units (“Units”) at a price of $0.25 per Unit for gross proceeds of $525,000. Each Unit consists of one common share of the Company (a “Share”) and one common share purchase warrant (a “Warrant”). Each Warrant entitles the holder thereof to purchase one additional Share at a price of $0.40 per Share at any time until November 30, 2017.

In connection with the Offering, the Company has paid Jordan Capital Markets Inc. a cash commission of $42,000 and issued 168,000 non-transferable agent warrants exercisable at $0.40 per share until November 30, 2017.

The net proceeds from the Offering are to be used for working capital purposes. All securities issued in connection with the Offering are subject to a four month statutory hold period expiring on March 31, 2013.

The Company also announces that Mr. Tariq Malik has resigned as Executive Vice-President and Chief Operating Officer effective November 30, 2012.

About Pan American Fertilizer Corp.

Pan American is a Canadian company dedicated to providing fertilizer to a growing global market. The company is focused on the extraction of a specific type of fertilizer called calcium sulphate (also referred to as “Agricultural Gypsum”). To ensure long term development and increase shareholder value, Pan American currently plans to significantly expand its current operational objectives while expanding its asset base by acquiring additional calcium sulphate and other fertilizer related assets.

When used as a fertilizer and as a soil remediator, calcium sulphate is a soft sulfate mineral composed of calcium sulfate dihydrate which is extremely rich in sulphur and calcium. When dissolved in water, the mineral becomes calcium and sulphate sulphur ions, both of which are required nutrients for plants. Calcium sulphate plays a vital role in establishing and maintaining good chemical balance in soil, water and plants, specifically with healthy root development. Ultimately, calcium sulphate increases overall crop quality and yields.

On behalf of the board of directors of Pan American Fertilizer Corp.

“Randy Wright”

Randy Wright
President and CEO

FOR MORE INFORMATION, PLEASE CONTACT:

Arwen Reynolds
areynolds@pafertilizer.com
(604)638-3480

Patriot Signs LOI For Additional Silver-Gold Project
Source: http://www.patriotminefinders.com/news/2012/november28/
November 28, 2012
Announcement Highlights:
Patriot able to earn 75% interest and become operator of KM 66 project
KM 66 project will be Patriot’s second in Central Mexico and will turn Patriot into a major explorer in the region
Project contains a deposit with compliant NI 43-101 (historical, 2008) resource of 22,297,800 silver equivalent ounces
Vancouver, B.C., Patriot Minefinders Inc. (“Patriot”, or the “Company”) (OTCBB: PROF) is pleased to announce that the Company has executed a Letter of Intent (“LOI”) with Bearing Resources Ltd. (“Bearing”) (TSX-V: BRZ) whereby Patriot may earn up to a 75% interest in the 13,400 hectare Kilometer 66 (“Km 66”, also known as Mapimi) silver-gold-lead-zinc property located in Durango, Mexico.
John H. Schweitzer, CEO states: “The Company is excited to be a part of Km 66 Project. This new venture together with La Buena project located 5.6 miles to the north of Goldcorp’s Penasquito mine will allow our Company to become a major explorer in the prolific silver-gold belt of Central Mexico. The Company believes that the silver-gold-lead-zinc mineralization identified to date on the Km 66 property may well be indicative of a larger system under shallow cover while the newly discovered Victorinos target illustrates the excellent exploration potential in the region.”
Km 66 Property
The Km 66 property, is located 100 kilometres from the Peñoles smelter at Torreon, and is bisected by a paved highway and power lines. Km 66 covers a five kilometre-long trend of mineralization that includes the La Gloria and Las Palmitas breccia-hosted epithermal silver-gold-lead-zinc deposits. Great Panther Silver Ltd. (“Great Panther”) which previously held an option to acquire Km 66 filed a technical report containing a mineral resource estimate compliant with NI 43-101 for the La Gloria and Las Palmitas deposits titled “Technical Report on the Mapimi Project, Mexico” dated May 8, 2008 and prepared by Wardrop Engineering (“Wardrop”) of Vancouver, B.C. (the “Technical Report”) (a copy of the Technical Report can be found at www.sedar.com under the profile of Great Panther). The Technical Report calculated a total of 22,297,800 silver equivalent ounces (6,585,900 tonnes grading 28 g/t silver, 0.09 g/t gold, 0.41% lead, 1.14% zinc) in the indicated category and a further 6,305,000 silver equivalent ounces (2,027,900 million tonnes grading 34 g/t silver, 0.13 g/t gold, 0.54% lead, 0.81% zinc) in the inferred category using a cut-off grade of 50 g/t silver equivalent. Metal prices and recoveries used Wardrop were US $9.55 per ounce and 76 per cent, respectively, for silver, US $530 per ounce and 70 per cent for gold, US $0.63 per pound and 80 per cent for lead, and US$1 per pound and 80 per cent for zinc.
Bearing and Patriot cautions the reader that the resource prepared by Wardrop for Great Panther is considered a “historical estimate” under NI 43-101 and a qualified person from the Companies have not done sufficient work to classify the historical estimate as a current mineral resource. Bearing and Patriot are not treating the historical estimate as a current mineral resource.
In addition to the La Gloria and Las Palmitas resource areas, drilling by Great Panther identified quartz-molybdenite veins in the Bull’s-Eye zone (186.22 metres grading 440ppm molybdenum) and carbonate replacement deposits in the e North Zone (2.14 metres grading 2.98% zinc and 0.41% lead). The Bull's-Eye zone is defined by a 2,000-by-800-metre induced polarization anomaly with a magnetic high near its centre. At the North Zone, mineralization is dominated by zinc with lesser amounts of lead, copper, gold and silver, and occurs in altered rhyolite sills, skarn altered limestone/marble, and in carbonate veinlets within the limestone/marble.
Recent work by Bearing has outlined a new target at Victorinos, some 5 Km east of la Gloria where soil sampling and prospecting have defined a 500m by 600m gold-silver-lead-zinc soil anomaly hosted by rhyolite. The target is a volcanic-hosted bulk-tonnage silver base metal deposit and rock sampling has indicated silver in sheeted and disseminated zones in altered rhyolite and local high grade silver base metal veins.
Option Terms
Under the terms of the Letter of Intent the companies will complete a Definitive Agreement that will include the following business terms. Patriot will be granted the right to earn a 75% interest in the property by assuming the remaining obligations of the underlying option agreement with the Mexican vendors who retain a 3% NSR.
-US$150,000 on signing the Definitive Agreement
-US$150,000 on the second anniversary
-US$400,000 on the second anniversary
-US$500,000 on the third anniversary
-US$7,875,000 at the end of year five
At Patriot’s election it may purchase the property outright on the first anniversary for US$5,575,000 or after the second anniversary for US$5,875,000 or after the third anniversary for US$6,875,000. The Company may purchase up to 1% of the NSR for US$650,000 per half percent and holds a first right of refusal to purchase the remaining 2%.
In addition Patriot must undertake work expenditures totaling US$2,000,000 before April 23, 2015 of which US$200,000 must be completed before April 23, 2013 (firm commitment), maintain the property in good standing, complete a bankable feasibility study by the eighth anniversary and pay to Bearing on signing of the definitive agreement 1,200,000 shares of Patriot. Should Patriot complete all its work commitments and payment obligations but fail to prepare a bankable feasibility study by the eighth anniversary it shall be deemed to have earned a 65% interest.
Completion of the transaction is subject to a number of conditions, including the appropriate regulatory approvals, and the negotiation and execution of a Definitive Agreement.
About Patriot Minefinders Inc.
Patriot is operated by a management team consisting of individuals with a track record of success in mining exploration, development and production. Patriot is an exploration company with focus on developing gold and silver deposits in the known mining districts in Mexico. Patriot’s first project is La Buena which is located only 5.6 miles north of Goldcorp's Peñasquito Mine. The La Buena Project is located in the mining friendly jurisdiction of Northern Zacatecas, Mexico. Patriot has an option to earn 50% of the La Buena project through an option agreement with a Canadian based mining exploration company. The execution of a Definitive Agreement on KM 66 Project with Bearing Resources Ltd. will turn Patriot into a major explorer in the prolific silver-gold belt of Central Mexico. Patriot trades under the symbol PROF.
Fred Tejada, P.Geo, Director of Patriot, is a qualified person within the context of National Instrument 43-101, and has read and takes responsibility for the technical content of this news release.

Applying The Venture Capital Model To Public Companies: Hugh Cleland - Interview with The Life Sciences Report

Source: http://bit.ly/10kEEh3

Hugh Cleland has been testing his theory that life sciences companies can be had cheaper as stocks than as private venture capital investments -- and that theory has been working out for him quite well over the past two years. In this interview with The Life Sciences Report,Cleland, portfolio manager and executive vice president at Toronto-based BluMont Capital, talks about his best small- and micro-cap ideas, and also shares the "core/farm team" approach that he takes in his smaller, more conventionally structured fund.

The Life Sciences Report: In your letter to investors dated October 12, you highlighted performance data for the BluMont Innovation PE Strategy Fund I, which showed a total return from the beginning of the year to September 30 of +30.75%. How was October?

Hugh Cleland: The BluMont Innovation PE Strategy Fund I takes a venture capital/private equity approach to publicly traded funds. That fund was up 3.46% in October. My more conventionally structured fund [it has monthly liquidity] is called the BluMont Northern Rivers Innovation Fund, and it is now up 22.19% year-to-date as of October 31, after rising more than 5% in October.

TLSR: Due diligence is important to you. Do you always meet management personally before you invest in small- and micro-cap companies?

HC: I meet with management multiple times before investing, but that is just one element of my due diligence process. In a step I consider even more important, I vet the company with my advisory board and network of field experts. My advisory board is comprised of a group of very successful scientists and entrepreneurs, including Harlan Waksal, the co-founder of ImClone Systems LLC, which was acquired by Eli Lilly and Co. (LLY) in 2008 for $6.5 billion [$6.5B]. There is also Tony Holler, the co-founder of ID Biomedical Corp., which was bought by GlaxoSmithKline (GSK) for CA$1.7B. Another is Gordon Glenn, who is the former CEO and chairman of SXC Health Solutions, which has been renamed Catamaran Corp. (CTRX) and now has a $10B market cap.

TLSR: Since so many don't make the grade, do you recommend that retail investors steer clear of micro-cap biotechnology and medical technology names?

HC: If retail investors are going to participate in micro-caps in general, and in micro-cap healthcare specifically, they need to be honest about their risk tolerance and only allocate money that they can afford to lose. Retail investors should also take a basket approach -- they should not put all their eggs in one basket. If possible, develop a network of experts, but do your own due diligence as well. Pay attention to balance sheets and cash needs as much as you can. It's not fun to get blindsided by financings or companies running out of money.

TLSR: Is dilution a major concern in these very small stocks?

HC: Financing and dilution are a big part of the micro-cap world. Investors have to keep that in mind when dealing with small companies. These factors should be a part of an investor's strategy when considering the micro-cap space.

TLSR: The other side of the dilution coin is that companies need capital to grow, correct?

HC: Yes. It is best to enter into a financing that meets the capital needs of a company and propels it through significant value-creation milestones. Retail investors don't always have that opportunity. For them, it's a matter of looking at the cash balance of the company and being comfortable with the idea that it has enough cash to see it through the process. Or an investor can enter after a financing, when he or she knows the company is in a position to meet its milestones and won't be subject to further dilution.

TLSR: That leads me to a question about one of your holdings, IntelGenx Corp. (IGXT.OB). In your recent newsletter, you voiced some frustration that a reasonable valuation has not been achieved, even though the company's major depressive disorder product, Forfivo XL [bupropion, an extended release, once-daily version of GlaxoSmithKline's Wellbutrin XL], is approved and on the market. Is it possible that the 505[2] process hasn't become a trend for investors?

HC: That is absolutely right. But I believe that among pharmaceutical companies -- and generics companies in particular -- the 505[2] pathway is going to become increasingly popular because it allows them to either repurpose existing drugs into new indications, or take existing drugs and put them in a new delivery vehicle that is more patient-friendly or more efficacious. Part of the reason a big valuation is not ascribed to a company like IntelGenx is that the 505[2] pathway isn't well known yet among investors. As it becomes more broadly accepted, both within industry and within the investor community, you will see valuations moving up on a secular basis over the next one to five years.

Let me give you an example of a 505[2] company that is somewhat similar to IntelGenx, but that has a much higher valuation. Supernus Pharmaceuticals Inc. (SUPN) has a valuation in the $300M range, as opposed to the $35M or so for IntelGenx. Supernus has a management team that Wall Street is comfortable with, and top-tier biotech venture capitalists as investors and board members. In my opinion, IntelGenx can earn that confidence and can achieve a valuation similar to Supernus after it hits a few more milestones, such as filing an abbreviated new drug application [ANDA] for its project with Par Pharmaceuticals, and filing an NDA for its migraine drug. Both filings are expected in Q1/13. Even a $200M valuation for IntelGenx would put it well above $3/share -- $3/share also happens to be the price target set by analyst Ram Selvaraju of Aegis Capital after IntelGenx launched its first drug on October 9.

TLSR: You cover other companies with interesting prospects. Go ahead and talk about one.

HC: I have deep familiarity with macular degeneration due to my participation in the $0.20 unit financing for iCo Therapeutics (ICOTF.PK) in November 2011. Diabetic macular edema [DME] is the lead indication for iCo. My advisory board was very enthusiastic about iCo for a variety of reasons, and the $0.20 unit, which was led by management and board members, has worked out very well, with the stock now trading good volume at around CA$0.70. If the phase 2 DME trials go the way we think they will, the stock should go significantly higher, likely into the $2-4 range. But it is not without risk.

TLSR: What strikes me about iCo is that it has an antisense molecule for neovascular disorders of the retina resulting from diabetes, and also has a monoclonal antibody, also for sight-threatening diseases. In addition, the company is developing a new delivery system for a very old antifungal drug, amphotericin B, for life-threatening disorders. Aren't these separate technologies a lot for this little company to tackle?

HC: Yes. But frankly, the only one I have paid attention to in my analysis -- and my reason for purchasing the company -- is the DME indication, which is now in a phase 2 trial. Perhaps I shouldn't, but I look at iCo as a single-indication company right now.

TLSR: Hugh, you own Neptune Technologies & Bioressources (NEPT), and you also own Acasti Pharma Inc. (ACPHF.OB), a majority-owned subsidiary of Neptune. The companies are tied together in development of krill oil products for high serum levels of lipids. They are not micro caps. And last week, an explosion and fire occurred at Neptune's production facility in Quebec. What is your expectation for the future of Neptune and Acasti?

HC: On October 2, Neptune completed a $34M financing, and at that point, the company's future never looked better. [I refer readers to my last research letter for a baseline view on Neptune and other core positions in the BluMont Innovation PE Strategy Fund I that apply the venture capital model to public companies.] Unfortunately, a horrendous tragedy befell the company on November 8, when its plant in Sherbrooke, Quebec, exploded. The human tragedy is first and foremost in this horrible turn of events, with 19 workers injured and three killed. But it is the curse of financial analysts and portfolio managers that we need to somehow put those things aside as we grapple with the business aspects of such tragedies. With that in mind, I refer your readers to a comment put out by Elemer Piros of Burrill and Company on November 11.

For those not familiar with Elemer Piros: He was the #1 ranked biotech analyst in the U.S. in 2010. He initiated coverage on Neptune in August 2012 with a $7 target. The main takeaway from his comment on Neptune following the explosion was very encouraging from an investment standpoint. He ran a hypothetical worst-case scenario, in which Neptune proves unable to produce product for a full year, and found that this subtracted only $0.68/share from his net present value [NPV]. Between this analysis, and Acasti stabilizing at levels higher than I was anticipating, I feel better about where Neptune might go when it reopens. Nothing, however, can make me feel better about the human tragedy involved.

Of course, there will be investors that panic out when the stock reopens, but there seem to be a good number of investors looking at this event to provide a compelling entry point.

TLSR: Amarin Corp.'s (AMRN) Vascepa [icosapent ethyl] for hypertriglyceridemia has been approved by the FDA. Acasti's CaPre [a purified extract from krill oil] is currently in two phase 2 trials for that same indication. Will uptake and sales of Vascepa be a guide as to how much CaPre can be worth?

HC: First, let me say that it was a relief to read in Acasti's November 12 press release that the company's ability to complete its two phase 2 trials, which are now well under way, is unaffected by the tragedy at Neptune's plant.

That said, I would point out that both Amarin's Vascepa and GSK's Lovaza [omega-3 acid ethyl esters] are guides to what Acasti's CaPre could be worth. We know that GSK sold more than $1B worth of Lovaza per year for several years, and that Reliant Pharmaceuticals Inc. [the company that sold and marketed Lovaza] was bought by GSK for $1.65B. We also know that investors have given Amarin a valuation ranging from $1-3B, on the basis of Vascepa being better than Lovaza in phase 3 trials. [Amarin still has no revenue.] If Acasti's CaPre can be shown to be better than Vascepa in clinical trials, you'd expect to see Acasti with a valuation above that of Amarin. Just for fun: A $1B valuation on Acasti would equate to $10/share, and a $3B valuation would equate to $30/share, after taking into account incremental dilution from the NASDAQ IPO required to raise money for Acasti's pivotal phase 3 trials.

An increasing number of investors in Neptune and Acasti are looking at CaPre as potentially better than Lovaza and Vascepa across all the lipid indications-triglycerides, low-density lipoproteins [LDLs] and high-density lipoproteins [HDLs]. If that's the case, and particularly if we can lower LDL by more than 6-10%, we will have a real blockbuster on our hands.

TLSR: The farm system has been a successful model for the San Francisco Giants, who just won their second World Series in three years. Many of the team's core players have come from the minor league San Jose Giants, affectionately known as the "Little Giants." Tell me about your farm team and how it works for you.

HC: I should first say that the farm team concept is only used in my more conventionally structured LP. I consider just about all the positions in the venture capital/private equity-structured LP to be core. With core positions, I am comfortable taking a five- or six-year view because I believe the companies are on a secular growth path, possessing a sustainable competitive advantage. I am happy to roll up my sleeves and do what I can to help create and realize value for companies I consider core positions. Turnover among core positions is extremely low.

Of course, core positions don't get that way overnight -- every core position started out as a farm team position. Core positions typically spent anywhere from 1-3 years on the farm team before graduating to core status. On the farm team, turnover can be high. Sometimes I take shorter-term [3- to 6-month], catalyst-driven positions for which I will maintain firm upside and stop-loss targets. I typically have pre-set sell targets [and stop-losses] for at least a portion of my farm team positions. The bottom line from a portfolio construction basis is that the venture capital/private equity-structured fund will only contain core positions. The more conventionally structured LP will contain both farm team and core positions, and will act as a "feeder system" for the successive venture capital/private equity-structured funds that I raise.

TLSR: Could you give me some farm team names, and make some very brief comments?

HC: Tekmira Pharmaceuticals Inc. (TKMR) and Allon Therapeutics Inc. (NPCUF.PK) are two great examples of farm team positions. Tekmira is an RNAi technology platform story. I bought Tekmira in its unit financing at $2.20 solely as a litigation/catalyst-driven position that appeared to have the odds stacked dramatically in its favor for a positive outcome. Tekmira was alleging license infringement and trade secret/intellectual property misappropriation by Alnylam Pharmaceuticals Inc. (ALNY). For a company facing such a binary event, there appeared to be unusually high downside protection [low initial valuation, good cash balance, a separate cash-generating business underpinning everything], combined with solid upside potential from a court case in which all the evidence I saw screamed "win" for Tekmira. [The litigation involved allegations of intellectual property/license infringement.]

Now that the company has favorably settled the litigation, I have taken my invested capital off the table by selling about 40% of my shares [while retaining the purchase warrants and the other 60% of the shares], and now I have to dig in to Tekmira's prospects as a drug developer before deciding how to proceed. Along those lines: Doug Loe at Byron Capital Markets, for whom I have a great deal of respect, raised his target to $12.50 on the back of this litigation win. Tekmira is certainly an example of a position that could evolve into a core position.

I established a farm team position in Allon Therapeutics in the $0.25/unit financing, after the company made a presentation to my advisory board. I had been following the company for years before buying. I was comfortable that Allon's change in indication (from Alzheimer's to an orphan neurological disease) was the right strategy, and that being able to invest in a phase 3 company with a $35M market cap provided a good risk-reward ratio for the farm team: On the back of successful phase 3 results, we would likely see analyst targets on Allon moving into the $2.50-5.00 range. On the other hand, a failed trial would see the stock go pretty close to zero. Again, the binary nature of the situation means Allon could never be a large position -- at least not until we see successful phase 3 results. Immuno Vaccine Inc. (IMMVF.PK) is another farm team position.

Senesco Technologies Inc. (SNT) is an anomaly: a core position with a farm team weighting. This company is developing a platform technology for addressing cancer. Management is working on a therapy that -- it is hoped -- triggers apoptotic cascades [cell death] in cancer cells while leaving healthy cells alone. Because of the dramatically binary nature of this opportunity, it is not possible to give this stock more than a 2% weight, but it is owned in both of the funds I manage. Results to date [both preclinical and clinical] are encouraging: The phase 1b/2a trial currently underway has a reasonable chance of giving us a "complete response" that could propel the stock up tenfold or more. The involvement of Harlan Waksal as chairman of Senesco is one of the key elements in my decision to include the company in both funds. But your readers should be reminded first that this type of stock could be a zero if the trial goes awry, and second to always do their own due diligence [financial and scientific] before purchasing any small- or micro-cap stock.

TLSR: Thanks for your time.

HC: My pleasure.

Pan American Fertilizer (CNSX: PAF) Chairman Letter to Shareholders


Source: http://bit.ly/TejPON

VANCOUVER, BRITISH COLUMBIA, November 22nd, 2012 - Pan American Fertilizer Corp., (CNSX: PAF) (“Pan American” or the “Company”) reports releases the following letter to its shareholders from its Chairman, Randy Wright.

Dear Shareholder,

Pan American recently announced the termination of our previously announced merger with Pacific Potash. Unfavorable market conditions were the key factor in the board’s decision to not move forward with the merger. The Company remains ideally positioned to take advantage of our rapidly increasing extraction rate at our Santiago Del Estero, Argentina site, as well as the steady increase in both local and international demand for our high quality product.

Our strategy remains based on the simple principal of supplying the highest quality product available to a continually growing robust market. As we move forward and meet both our extraction and sales milestones, our revenue stream will allow us to also pursue value added transactions with local Argentinean and international partners while avoiding significant share dilution. We will continue to remain open to new opportunities that will leverage our proven asset and position us to meet our long term vision of becoming a major global fertilizer supplier.

Your Board of Directors and management team remain dedicated to increasing shareholder value, and we continue to be motivated by the prospects of the Company. I would like to personally thank each of you, and will work to ensure your trust is maintained as Pan American grows.

Sincerely,

“Randy Wright”

Randy Wright
Chairman, President and CEO

First Liberty Power Acquires Uranium & Vanadium Property in Utah

Source: http://bit.ly/SOlt8S

LAS VEGAS, Nov. 20, 2012 /PRNewswire/ -- First Liberty Power Corp. (OTCQB: FLPC) is pleased to announce that it has entered into an agreement to acquire a Vanadium & Uranium property in San Juan county, Utah.

The property is comprised of 13 lode claims, totaling 260 acres (the "San Juan Property"), located within the Colorado Plateau near the Utah-Colorado border. A preliminary radon survey was completed on the San Juan Property in 2009 and it indicated an anomalous east-west radiometric trend. The size of the anomalies appear to be very similar to the size of the high grade vanadium-uranium beds mined from the nearby Firefly, Gray Daun and Vanadium Queen Mines. This channel system, which was already delineated by the radon survey, is part of the system that hosts the Pandora and Beaver Shaft mines - both of which are producing Uranium and Vanadium ore that is transported to and processed at the Dennison Mill located near Blanding Utah.

The most significant commercial use for uranium is to fuel nuclear reactors for electricity generation. There are 440 reactors operating worldwide and a total of 60 new reactors that are under construction. With estimates of over 150 power reactors, with a total net capacity of some 172,000 MWe, planned and over 340 more proposed (as of August 2011), we expect the demand for uranium to increase significantly.

Vanadium has several industrial uses, particularly as an alloy in iron and steel, specifically for its weight-saving benefits in high-strength steel. Vanadium is also a critical component in Vanadium Redox batteries, which have an extremely large capacity potential - making them well suited for use in large power variable storage applications, such as with wind or solar power. The limited self-discharge characteristics of vanadium redox batteries also make them useful in applications where the batteries must be stored for long periods of time in a ready state with little maintenance.

First Liberty Power Corp. continues to execute on its broad strategy to expand into multiple strategic elements and to develop its US based exploration and mining operations. By acquiring this Vanadium & Uranium property, First Liberty has now formed a core group of mining activities for the future. In combination with our key ownership interests in Lithium and Antimony properties, we have brought together the strategic and critical elements we believe will assist the company in the further development and growth the of the alternative energy sector.

Mr. Don Nicholson, CEO, emphasized, "Management is very pleased to again have the opportunity to work with GeoXplor Corp in furthering the development of this highly prospective property. The combination of the positive indications of the initial radon survey, as well as the historical and active production on nearby and adjacent properties has provided our team with a great degree of confidence for a successful mining operation in the near future. For our next exploration stage, we will undertake a more granular radon survey, which we trust will provide us with the specific targets for a follow-on 10,000 foot confirmation drill program." The CEO went on further to say, "The management team is working relentlessly to make our vision of a truly comprehensive and diversified mining operation a reality. We continue to put the pieces in place to be a company that meets the needs of our emerging energy technologies of today and tomorrow. Finally, we see the addition of these strategic elements as a direct path to delivering increased revenue streams and ultimately boosting shareholder value."

About Us

First Liberty is a Nevada based mineral exploration company with a focus on the exploration, development, mining and refining of strategic industrial metals in the USA. With a foundation in lithium exploration and a recent addition of antimony mining and development, together with the exploration of Uranium and Vanadium, it is our vision to significantly contribute towards ensuring a domestic supply of those strategic mineral elements that are critical to current and emerging technologies. We will continue assembling a portfolio of properties and interests in several key areas, ranging in developmental to advanced stage exploration, to those being production ready.

Pemex Embraces New Technology to Increase Output - NXT Energy's SFD technology is the focus


Excerpt from the news release:
"Current annual global geophysical exploration spending is around $12 billion. NXT’s partnership with Pemex is an important milestone for the company. If the relationship goes well, expect NXT to be signing new contracts with international oil and gas companies looking to gain a technological advantage." - YahooFinance

Source: http://yhoo.it/TMKfFHhttp://